ArticleEndocrine connections2026
The EuRREB Core Endocrine Registry and its potential for studying transition of care in Endo-ERN centres.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractNatural history registries can address knowledge gaps and support the development of best practice guidelines to improve outcomes in rare conditions. The European Registries for Rare Endocrine and Bone conditions (EuRREB) Core Registry is a standardised, multi-national platform designed to collect harmonised clinical data across rare endocrine disorders and facilitate longitudinal real-world analyses. The aim of this study was to describe data collected in the Core Registry across eight endocrine main thematic groups (MTGs) during the first six years following its launch in 2019, with a particular focus on the transition period, defined as 14-25 years of age. Forty-eight centres from 20 European and non-European countries contributed data, of which 33 (69%) were members of the European Reference Network on rare endocrine conditions (Endo-ERN). A total of 3,225 unique patients were registered, with a median age of 37 years. Overall, the hypothalamic and pituitary MTG accounted for the largest number of records (n = 1,548). The highest proportion of patients in the transition age group was observed in the sex development and maturation MTG (66%, 445/677), followed by thyroid (33%, 86/260) and growth and genetic obesity (32%, 42/130). A total of 303 patients had an active platform account, and 85 completed patient-reported outcome measures. Clinicians completed a total of 2,390 condition-specific outcomes. These findings demonstrate the capacity of the Core Registry to generate real-world insights across rare endocrine conditions and age groups. The observed transition-age representation highlights an opportunity to strengthen structured pathways and support continuity of care across the paediatric-adult interface. PLAIN LANGUAGE SUMMARY: The European Registries for Rare Endocrine and Bone conditions (EuRREB), supported by the Endo-ERN, collects information on rare diseases to improve care. This study shares what we learned over six years, including how young people move from paediatric to adult care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.